Serotonin receptor agonist and risk of paresthesia in migraine patients: A dose-response model-based (network) meta-analysis
Background: Migraine may be an important factor for paresthesia in the limbs, especially in the upper limbs. In several patients, paresthesia is responsible for a low quality of life. Treatment with the serotonin agonist may be a triggering factor for paresthesia in certain patients. Various seroton...
Main Authors: | Sayed Aliul Hasan Abdi, Shabihul Fatma Sayed, Jamuna Bhaskar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Annals of Indian Academy of Neurology |
Subjects: | |
Online Access: | http://www.annalsofian.org/article.asp?issn=0972-2327;year=2022;volume=25;issue=4;spage=669;epage=675;aulast=Hasan |
Similar Items
-
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential
by: Negro A, et al.
Published: (2018-03-01) -
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2020-06-01) -
Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
by: Andrew Blumenfeld, et al.
Published: (2023-10-01) -
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials
by: Xinxin Deng, et al.
Published: (2024-02-01) -
Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
by: Timothy Smith, et al.
Published: (2020-05-01)